SELLAS Life Sciences Group, Inc. (SLS)

USD 0.84

(-4.62%)

Market Cap (In USD)

59.19 Million

Revenue (In USD)

-

Net Income (In USD)

-37.34 Million

Avg. Volume

641.55 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.5-1.72
PE
-
EPS
-
Beta Value
2.396
ISIN
US81642T2096
CUSIP
81642T209
CIK
1390478
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Angelos M. Stergiou M.D., ScD h.c.
Employee Count
-
Website
https://www.sellaslifesciences.com
Ipo Date
2008-03-12
Details
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.